{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:05:54Z","timestamp":1774065954112,"version":"3.50.1"},"reference-count":65,"publisher":"Harborside Press, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"Background:<\/jats:bold> Physical activity (PA) and dexamethasone (Dex) when used independently have modest benefits for cancer-related fatigue (CRF) in patients with advanced cancer. In this study we aimed to determine the feasibility (adherence, safety, and satisfaction) of combining PA with Dex versus PA with placebo (PBO) for CRF, and to explore the effects of PA+Dex and PA+PBO on CRF. Patients and Methods:<\/jats:bold> In this phase II, randomized, double-blind controlled trial, eligible patients had advanced cancer and a CRF score of \u22654 on the Edmonton Symptom Assessment Scale (ESAS) for fatigue (0\u201310 scale). Patients were randomized to standardized PA for 4 weeks with either 4 mg of Dex (PA+Dex arm) or PBO (PA+PBO arm) twice daily for the first 7 days. Changes in Functional Assessment of Chronic Illness Therapy\u2013Fatigue (FACIT-F) scores from baseline to days 8 and 29 were assessed. Other outcomes included change in quality-of-life scores. Results:<\/jats:bold> A total of 64 (89%) patients were evaluable. Adherence rates for study medication, resistance exercise, and aerobic exercise were 91% and 92% (P<\/jats:italic>=.15), 83% and 70.6% (P<\/jats:italic>=.35), and 82.9% and 78.3% (P<\/jats:italic>=.73), respectively, in the PA+Dex and PA+PBO arms. The satisfaction rates for the PA+Dex and PA+PBO arms were 98% and 79%, respectively. Median (IQR) changes in FACIT-F scores at days 8 and 29 from baseline were 9 (2 to 16; P<\/jats:italic><.001) and 5.75 (0 to 12.5; P<\/jats:italic>=.015) for the PA+Dex arm, respectively, and 3.5 (\u22122.1 to 10; P<\/jats:italic>=.054) and 6.5 (2.5 to 15.5; P<\/jats:italic>=.006) for the PA+PBO arm, respectively. We found a significant treatment effect in the PA+Dex arm using exploratory linear mixed model analysis, with treatment showing an improvement of 5.63 units for FACIT-F scores (95% CI, 1.74\u20139.52; P<\/jats:italic>=.005). We found significant improvement in Functional Assessment of Cancer Therapy-General (FACT-G), Patient-Reported Outcomes Measurement Information System-Fatigue Short Form 7a (PROMIS-Fatigue SF-7a), and Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) totals on days 8 and 29 in the PA+Dex arm. There was no significant difference in grade \u22653 adverse events between the arms (P<\/jats:italic>=.36). Conclusions:<\/jats:bold> Our study found that the use of combination PA+Dex and PA+PBO for CRF was feasible and associated with high rates of satisfaction, adherence to medication and PA intervention, and tolerability. CRF improvement with PA+Dex was clinically significant at days 8 and 29. Further larger studies are justified.<\/jats:p>\nClinicalTrials.gov identifier:<\/jats:bold> NCT03583255<\/jats:ext-link><\/jats:p>","DOI":"10.6004\/jnccn.2024.7071","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T15:54:00Z","timestamp":1736265240000},"source":"Crossref","is-referenced-by-count":3,"title":["Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial"],"prefix":"10.6004","volume":"23","author":[{"given":"Sriram","family":"Yennurajalingam","sequence":"first","affiliation":[{"name":"Division of Cancer, Department of Palliative Care, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon G.","family":"Smalgo","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravind","family":"Dasari","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanwal Pratap Singh","family":"Raghav","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos H.","family":"Barcenas","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naifa L.","family":"Busaidy","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Fellman","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Basen-Engquist","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debasish","family":"Tripathy","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[{"name":"Division of Cancer, Department of Palliative Care, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"J Natl Compr Canc Netw","first-page":"1012","article-title":"Cancer-related fatigue, version 2.2015","volume":"13","author":"Berger AM","year":"2015","unstructured":"Berger AM, Mooney K, Alvarez-Perez A, Cancer-related fatigue, version 2.2015. J Natl Compr Canc Netw 2015;13:1012\u20131039."},{"key":"B2","series-title":"Nat Rev Clin Oncol","first-page":"597","article-title":"Cancer-related fatigue\u2013mechanisms, risk factors, and treatments","volume":"11","author":"Bower JE","year":"2014","unstructured":"Bower JE. Cancer-related fatigue\u2013mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 2014;11:597\u2013609."},{"key":"B3","series-title":"Curr Treat Options Oncol","first-page":"93","article-title":"Management of fatigue in patients with advanced cancer","volume":"24","author":"Stone P","year":"2023","unstructured":"Stone P, Candelmi DE, Kandola K, Management of fatigue in patients with advanced cancer. Curr Treat Options Oncol 2023;24:93\u2013107."},{"key":"B4","series-title":"Biomed Res Int","first-page":"3989286","article-title":"Cancer related fatigue and quality of life in patients with advanced prostate cancer undergoing chemotherapy","volume":"2016","author":"Charalambous A","year":"2016","unstructured":"Charalambous A, Kouta C. Cancer related fatigue and quality of life in patients with advanced prostate cancer undergoing chemotherapy. Biomed Res Int 2016;2016:3989286."},{"key":"B5","series-title":"Oncologist","first-page":"4","article-title":"Cancer-related fatigue: the scale of the problem","volume":"12","author":"Hofman M","year":"2007","unstructured":"Hofman M, Ryan JL, Figueroa-Moseley CD, Cancer-related fatigue: the scale of the problem. Oncologist 2007;12(Suppl 1):4\u201310."},{"key":"B6","series-title":"J Natl Compr Canc Netw","first-page":"448","article-title":"Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy","volume":"6","author":"Butt Z","year":"2008","unstructured":"Butt Z, Rosenbloom SK, Abernethy AP, Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 2008;6:448\u2013455."},{"key":"B7","series-title":"Oncology (Williston Park)","first-page":"369","article-title":"Progress toward guidelines for the management of fatigue","volume":"12","author":"Cella D","year":"1998","unstructured":"Cella D, Peterman A, Passik S, Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998;12:369\u2013377."},{"key":"B8","series-title":"Cancers (Basel)","first-page":"91","article-title":"Meta-analysis of pharmacological, nutraceutical and phytopharmaceutical interventions for the treatment of cancer related fatigue","volume":"15","author":"Yennurajalingam S","year":"2022","unstructured":"Yennurajalingam S, Lu Z, Rozman De Moraes A, Meta-analysis of pharmacological, nutraceutical and phytopharmaceutical interventions for the treatment of cancer related fatigue. Cancers (Basel) 2022;15:91."},{"key":"B9","series-title":"J Clin Oncol","first-page":"905","article-title":"Palliative care and the management of common distressing symptoms in advanced cancer: pain, breathlessness, nausea and vomiting, and fatigue","volume":"38","author":"Henson LA","year":"2020","unstructured":"Henson LA, Maddocks M, Evans C, Palliative care and the management of common distressing symptoms in advanced cancer: pain, breathlessness, nausea and vomiting, and fatigue. J Clin Oncol 2020;38:905\u2013914."},{"key":"B10","series-title":"Cochrane Database Syst Rev","first-page":"CD012685","article-title":"Exercise training for advanced lung cancer","volume":"2017","author":"Peddle\u2010McIntyre CJ","year":"2017","unstructured":"Peddle\u2010McIntyre CJ, Singh F, Thomas R, Exercise training for advanced lung cancer. Cochrane Database Syst Rev 2017;2017:CD012685."},{"key":"B11","series-title":"J Pain Symptom Manage","first-page":"899","article-title":"The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: a meta-analysis of randomized control trials","volume":"58","author":"Nadler MB","year":"2019","unstructured":"Nadler MB, Desnoyers A, Langelier DM, Amir E. The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: a meta-analysis of randomized control trials. J Pain Symptom Manage 2019;58:899\u2013908.e7."},{"key":"B12","series-title":"Prev Med","first-page":"124","article-title":"Exercise interventions for individuals with advanced cancer: a systematic review","volume":"104","author":"Dittus KL","year":"2017","unstructured":"Dittus KL, Gramling RE, Ades PA. Exercise interventions for individuals with advanced cancer: a systematic review. Prev Med 2017;104:124\u2013132."},{"key":"B13","series-title":"Ann Oncol","first-page":"713","article-title":"Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment","volume":"31","author":"Fabi A","year":"2020","unstructured":"Fabi A, Bhargava R, Fatigoni S, Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann Oncol 2020;31:713\u2013723."},{"key":"B14","series-title":"J Cancer Surviv","first-page":"399","article-title":"The effects of physical exercise in the palliative care phase for people with advanced cancer: a systematic review with meta-analysis","volume":"17","author":"Toohey K","year":"2023","unstructured":"Toohey K, Chapman M, Rushby AM, The effects of physical exercise in the palliative care phase for people with advanced cancer: a systematic review with meta-analysis. J Cancer Surviv 2023;17:399\u2013415."},{"key":"B15","series-title":"Cochrane Database Syst Rev","first-page":"CD006788","article-title":"Pharmacological treatments for fatigue associated with palliative care","volume":"10","author":"Peuckmann\u2010Post V","year":"2010","unstructured":"Peuckmann\u2010Post V, Elsner F, Krumm N, Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2010;10:CD006788."},{"key":"B16","series-title":"Cancer J","first-page":"319","article-title":"Review of clinical trials of pharmacologic interventions for cancer-related fatigue: focus on psychostimulants and steroids","volume":"20","author":"Yennurajalingam S","year":"2014","unstructured":"Yennurajalingam S, Bruera E. Review of clinical trials of pharmacologic interventions for cancer-related fatigue: focus on psychostimulants and steroids. Cancer J 2014;20:319\u2013324."},{"key":"B17","series-title":"Cancer Treat Rep","first-page":"751","article-title":"Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study","volume":"69","author":"Bruera E","year":"1985","unstructured":"Bruera E, Roca E, Cedaro L, Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985;69:751\u2013754."},{"key":"B18","series-title":"Cochrane Database Syst Rev","first-page":"CD006788.","article-title":"Pharmacological treatments for fatigue associated with palliative care","author":"Peuckmann V","year":"2010","unstructured":"Peuckmann V, Elsner F, Krumm N, Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2010:CD006788."},{"key":"B19","series-title":"Support Care Cancer","first-page":"386","article-title":"The use of corticosteroids in home palliative care","volume":"9","author":"Mercadante S","year":"2001","unstructured":"Mercadante S, Fulfaro F, Casuccio A. The use of corticosteroids in home palliative care. Support Care Cancer 2001;9:386\u2013389."},{"key":"B20","series-title":"J Clin Oncol","first-page":"3299","article-title":"Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia\/cachexia","volume":"17","author":"Loprinzi CL","year":"1999","unstructured":"Loprinzi CL, Kugler JW, Sloan JA, Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia\/cachexia. J Clin Oncol 1999;17:3299\u20133306."},{"key":"B21","series-title":"Postgrad Med J","first-page":"702","article-title":"Corticosteroids in terminal cancer\u2013a prospective analysis of current practice","volume":"59","author":"Hanks GW","year":"1983","unstructured":"Hanks GW, Trueman T, Twycross RG. Corticosteroids in terminal cancer\u2013a prospective analysis of current practice. Postgrad Med J 1983;59:702\u2013706."},{"key":"B22","series-title":"Eur J Cancer Clin Oncol","first-page":"1817","article-title":"Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study","volume":"25","author":"Metz CA","year":"1989","unstructured":"Metz CA, Robustelli Della Cuna G, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. Eur J Cancer Clin Oncol 1989;25:1817\u20131821."},{"key":"B23","series-title":"Cancer","first-page":"1607","article-title":"Corticosteroid therapy of preterminal gastrointestinal cancer","volume":"33","author":"Moertel CG","year":"1974","unstructured":"Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607\u20131609."},{"key":"B24","series-title":"J Clin Oncol","first-page":"2456","article-title":"Management of fatigue in adult survivors of cancer: ASCO\u2013Society for Integrative Oncology guideline update","volume":"42","author":"Bower JE","year":"2024","unstructured":"Bower JE, Lacchetti C, Alici Y, Management of fatigue in adult survivors of cancer: ASCO\u2013Society for Integrative Oncology guideline update. J Clin Oncol 2024;42:2456\u20132487."},{"key":"B25","article-title":"Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue","author":"Jankowski C","unstructured":"Jankowski C, Carpenter KM, Aranha O, Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 2.2024. Accessed October 10, 2024. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B26","series-title":"J Clin Oncol","first-page":"3076","article-title":"Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer","volume":"31","author":"Yennurajalingam S","year":"2013","unstructured":"Yennurajalingam S, Frisbee-Hume S, Palmer JL, Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013;31:3076\u20133082."},{"key":"B27","series-title":"Cancer Med","first-page":"3714","article-title":"Impact of physical exercise in advanced-stage cancer patients: systematic review and meta-analysis","volume":"11","author":"Rodr\u00edguez-Ca\u00f1amero S","year":"2022","unstructured":"Rodr\u00edguez-Ca\u00f1amero S, Cobo-Cuenca AI, Carmona-Torres JM, Impact of physical exercise in advanced-stage cancer patients: systematic review and meta-analysis. Cancer Med 2022;11:3714\u20133727."},{"key":"B28","series-title":"JAMA Oncol","first-page":"961","article-title":"Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis","volume":"3","author":"Mustian KM","year":"2017","unstructured":"Mustian KM, Alfano CM, Heckler C, Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017;3:961\u2013968."},{"key":"B29","series-title":"J Natl Compr Canc Netw","first-page":"235","article-title":"Combination therapy of physical activity and dexamethasone for cancer-related fatigue: a phase II randomized double-blind controlled trial","volume":"20","author":"Yennurajalingam S","year":"2021","unstructured":"Yennurajalingam S, Valero V, Lu Z, Combination therapy of physical activity and dexamethasone for cancer-related fatigue: a phase II randomized double-blind controlled trial. J Natl Compr Canc Netw 2021;20:235\u2013243."},{"key":"B30","series-title":"Med Sci Sports Exerc","first-page":"1859","article-title":"Mediators of exercise effects on HRQoL in cancer survivors after chemotherapy","volume":"48","author":"Kalter J","year":"2016","unstructured":"Kalter J, Kampshoff CS, Chinapaw MJM, Mediators of exercise effects on HRQoL in cancer survivors after chemotherapy. Med Sci Sports Exerc 2016;48:1859\u20131865."},{"key":"B31","series-title":"Med Sci Sports Exerc","first-page":"970","article-title":"Exercise mechanisms to reduce fatigue in cancer survivors","volume":"55(Suppl 9)","author":"Mast IH","year":"2023","unstructured":"Mast IH, Bongers CCWG, Gootjes E, Exercise mechanisms to reduce fatigue in cancer survivors. Med Sci Sports Exerc 2023;55(Suppl 9):970. Abstract 2842."},{"key":"B32","series-title":"J Cancer Surviv.","article-title":"Potential mechanisms underlying the effect of walking exercise on cancer-related fatigue in cancer survivors","author":"Mast IH","unstructured":"Mast IH, Bongers CCWG, Gootjes EC, Potential mechanisms underlying the effect of walking exercise on cancer-related fatigue in cancer survivors. J Cancer Surviv. Published online January 31, 2024. doi.org\/10.1007\/s11764-024-01537-y"},{"key":"B33","series-title":"Med Sci Sports Exerc","first-page":"496","article-title":"Inflammation mediates exercise effects on fatigue in patients with breast cancer","volume":"53","author":"Hiensch AE","year":"2021","unstructured":"Hiensch AE, Mijwel S, Bargiela D, Inflammation mediates exercise effects on fatigue in patients with breast cancer. Med Sci Sports Exerc 2021;53:496\u2013504."},{"key":"B34","series-title":"Breast","first-page":"166","article-title":"The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: a meta-analysis","volume":"33","author":"Juvet LK","year":"2017","unstructured":"Juvet LK, Thune I, Elvsaas I, The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: a meta-analysis. Breast 2017;33:166\u2013177."},{"key":"B35","series-title":"Curr Treat Options Oncol","first-page":"796","article-title":"Do patients benefit from a trial of corticosteroids at the end of life?","volume":"23","author":"Yennurajalingam S","year":"2022","unstructured":"Yennurajalingam S, Bruera E. Do patients benefit from a trial of corticosteroids at the end of life? Curr Treat Options Oncol 2022;23:796\u2013805."},{"key":"B36","series-title":"Oncologist","first-page":"384","article-title":"Effects of dexamethasone and placebo on symptom clusters in advanced cancer patients: a preliminary report","volume":"21","author":"Yennurajalingam S","year":"2016","unstructured":"Yennurajalingam S, Williams JL, Chisholm G, Bruera E. Effects of dexamethasone and placebo on symptom clusters in advanced cancer patients: a preliminary report. Oncologist 2016;21:384\u2013390."},{"key":"B37","series-title":"J Palliat Care","first-page":"6","article-title":"The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients","volume":"7","author":"Bruera E","year":"1991","unstructured":"Bruera E, Kuehn N, Miller MJ, The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6\u20139."},{"key":"B38","series-title":"J Pain Symptom Manage","first-page":"128","article-title":"The Memorial Delirium Assessment Scale","volume":"13","author":"Breitbart W","year":"1997","unstructured":"Breitbart W, Rosenfeld B, Roth A, The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997;13:128\u2013137."},{"key":"B39","series-title":"Acta Psychiatr Scand","first-page":"361","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond AS","year":"1983","unstructured":"Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361\u2013370."},{"key":"B40","series-title":"J Pain Symptom Manage","first-page":"547","article-title":"Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella D","year":"2002","unstructured":"Cella D, Eton DT, Lai JS, Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547\u2013561."},{"key":"B41","series-title":"J Pain Symptom Manage","first-page":"604","article-title":"Multidimensional independent predictors of cancer-related fatigue","volume":"26","author":"Hwang SS","year":"2003","unstructured":"Hwang SS, Chang VT, Rue M, Kasimis B. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage 2003;26:604\u2013614."},{"key":"B42","series-title":"J Clin Epidemiol","first-page":"507","article-title":"Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients","volume":"64","author":"Yost KJ","year":"2011","unstructured":"Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol 2011;64:507\u2013516."},{"key":"B43","series-title":"J Clin Epidemiol","first-page":"1179","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella D","year":"2010","unstructured":"Cella D, Riley W, Stone A, The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol 2010;63:1179\u20131194."},{"key":"B44","series-title":"J Pain Symptom Manage","first-page":"14","article-title":"Further validation of the Multidimensional Fatigue Symptom Inventory-Short Form","volume":"27","author":"Stein KD","year":"2004","unstructured":"Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the Multidimensional Fatigue Symptom Inventory-Short Form. J Pain Symptom Manage 2004;27:14\u201323."},{"key":"B45","series-title":"J Natl Cancer Inst","first-page":"1155","article-title":"A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue","volume":"100","author":"Minton O","year":"2008","unstructured":"Minton O, Richardson A, Sharpe M, A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008;100:1155\u20131166."},{"key":"B46","series-title":"J Clin Oncol","article-title":"Dexamethasone (DM) for cancer-related fatigue: a double-blinded, randomized, placebo-controlled trial","author":"Yennurajalingam S","year":"2012;30","unstructured":"Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, Dexamethasone (DM) for cancer-related fatigue: a double-blinded, randomized, placebo-controlled trial. J Clin Oncol 2012;30(Suppl 15):Abstract 9002."},{"key":"B47","series-title":"J Clin Oncol","first-page":"3475","article-title":"Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial","volume":"25","author":"Bruera E","year":"2007","unstructured":"Bruera E, El Osta B, Valero V, Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2007;25:3475\u20133481."},{"key":"B48","series-title":"J Clin Oncol","first-page":"4439","article-title":"Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report","volume":"21","author":"Bruera E","year":"2003","unstructured":"Bruera E, Driver L, Barnes EA, Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003;21:4439\u20134443."},{"key":"B49","series-title":"J Clin Oncol","first-page":"2073","article-title":"Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial","volume":"24","author":"Bruera E","year":"2006","unstructured":"Bruera E, Valero V, Driver L, Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006;24:2073\u20132078."},{"key":"B50","series-title":"J Clin Oncol","first-page":"570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella DF","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570\u2013579."},{"key":"B51","series-title":"Support Care Cancer","first-page":"191","article-title":"Systematic review of the multidimensional fatigue symptom inventory-short form","volume":"23","author":"Donovan KA","year":"2015","unstructured":"Donovan KA, Stein KD, Lee M, Systematic review of the multidimensional fatigue symptom inventory-short form. Support Care Cancer 2015;23:191\u2013212."},{"key":"B52","series-title":"Eur J Cancer","first-page":"1863","article-title":"A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients","volume":"47","author":"Carvajal A","year":"2011","unstructured":"Carvajal A, Centeno C, Watson R, Bruera E. A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients. Eur J Cancer 2011;47:1863\u20131872."},{"key":"B53","series-title":"Cancer","first-page":"2164","article-title":"Validation of the Edmonton Symptom Assessment Scale","volume":"88","author":"Chang VT","year":"2000","unstructured":"Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000;88:2164\u20132171."},{"key":"B54","series-title":"J Pain Symptom Manage","first-page":"297","article-title":"The association of physical and psychological symptom burden with time to death among palliative cancer outpatients","volume":"37","author":"Cheung WY","year":"2009","unstructured":"Cheung WY, Barmala N, Zarinehbaf S, The association of physical and psychological symptom burden with time to death among palliative cancer outpatients. J Pain Symptom Manage 2009;37:297\u2013304."},{"key":"B55","series-title":"Curr Oncol","first-page":"55.","article-title":"A review of the reliability and validity of the Edmonton Symptom Assessment System","volume":"16","author":"Richardson LA","year":"2009","unstructured":"Richardson LA, Jones GW. A review of the reliability and validity of the Edmonton Symptom Assessment System. Curr Oncol 2009;16:55."},{"key":"B56","series-title":"J Psychosom Res","first-page":"579","article-title":"Construct validation of the hospital anxiety and depression scale with clinical populations","volume":"48","author":"Johnston M","year":"2000","unstructured":"Johnston M, Pollard B, Hennessey P. Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosom Res 2000;48:579\u2013584."},{"key":"B57","series-title":"J Pain Symptom Manage","first-page":"587","article-title":"Cancer-related fatigue: central or peripheral?","volume":"38","author":"Yavuzsen T","year":"2009","unstructured":"Yavuzsen T, Davis MP, Ranganathan VK, Cancer-related fatigue: central or peripheral? J Pain Symptom Manage 2009;38:587\u2013596."},{"key":"B58","series-title":"Brain Behav Immun","first-page":"S48","article-title":"Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications","volume":"30(Suppl)","author":"Bower JE","year":"2013","unstructured":"Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun 2013;30(Suppl):S48\u201357."},{"key":"B59","series-title":"Support Care Cancer","first-page":"2461","article-title":"The biology of cancer-related fatigue: a review of the literature","volume":"23","author":"Saligan LN","year":"2015","unstructured":"Saligan LN, Olson K, Filler K, The biology of cancer-related fatigue: a review of the literature. Support Care Cancer 2015;23:2461\u20132478."},{"key":"B60","series-title":"Oncologist","first-page":"1649","article-title":"Physical exercise for cancer patients with advanced disease: a randomized controlled trial","volume":"16","author":"Oldervoll LM","year":"2011","unstructured":"Oldervoll LM, Loge JH, Lydersen S, Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 2011;16:1649\u20131657."},{"key":"B61","series-title":"Psychooncology","first-page":"713","article-title":"Predictors of adherence to exercise interventions during and after cancer treatment: a systematic review","volume":"27","author":"Ormel HL","year":"2018","unstructured":"Ormel HL, van der Schoot GGF, Sluiter WJ, Predictors of adherence to exercise interventions during and after cancer treatment: a systematic review. Psychooncology 2018;27:713\u2013724."},{"key":"B62","series-title":"Oncologist","first-page":"1081","article-title":"Open-label placebo for the treatment of cancer-related fatigue in patients with advanced cancer: a randomized controlled trial","volume":"27","author":"Yennurajalingam S","year":"2022","unstructured":"Yennurajalingam S, Azhar A, Lu Z, Open-label placebo for the treatment of cancer-related fatigue in patients with advanced cancer: a randomized controlled trial. Oncologist 2022;27:1081\u20131089."},{"key":"B63","series-title":"Sci Rep","first-page":"2784.","article-title":"Open-label placebo treatment for cancer-related fatigue: a randomized-controlled clinical trial","volume":"8","author":"Hoenemeyer TW","year":"2018","unstructured":"Hoenemeyer TW, Kaptchuk TJ, Mehta TS, Fontaine KR. Open-label placebo treatment for cancer-related fatigue: a randomized-controlled clinical trial. Sci Rep 2018;8:2784."},{"key":"B64","series-title":"Oncologist","first-page":"354","article-title":"A systematic review of adherence to oral antineoplastic therapies","volume":"21","author":"Greer JA","year":"2016","unstructured":"Greer JA, Amoyal N, Nisotel L, A systematic review of adherence to oral antineoplastic therapies. Oncologist 2016;21:354\u2013376."},{"key":"B65","series-title":"Cancer","first-page":"2552","article-title":"Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: a randomized controlled trial","volume":"124","author":"Scott JM","year":"2018","unstructured":"Scott JM, Iyengar NM, Nilsen TS, Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: a randomized controlled trial. Cancer 2018;124:2552\u20132560."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/1\/article-e247071.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/1\/article-e247071.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/1\/article-e247071.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T13:55:25Z","timestamp":1736949325000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/1\/article-e247071.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":65,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.7071","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}